TCL Archive FDA Approved 88% Of Cancer Applications Since Oncology Office Opened In 2005. July 3, 2008
TCL Archive EntreMed Begins Pilot Phase II Trial Of Small Molecule Angiogenesis Inhibitor. December 15, 2000
TCL Archive New Seer Report Says Five Year Relative Survival At 49 Per Cent Over all, 50 Per Cent For White November 30, 1984
